Blood Based Assessment of sST2, Taken During and After Surgery, for Pediatric Patients With Heart Defects to Predict Heart Failure.
Biomarker in Congenital Cardiac Surgery - sST2 Marker in Heart Failure in Congenital Heart Disease After Surgery Research and Translational Study
Martin Schweiger
225 participants
Sep 10, 2025
OBSERVATIONAL
Conditions
Summary
Patients younger than 18 scheduled for congenital heart surgery will be assessed during and post-operatively as well as at the first follow-up after 9-12 month for the novel biomarker sST2. We will assess the marker independently and in evaluation with other blood biomarkers to evaluate sings of heart failure. Compared to established biomarkers, sST2 promises thereby to be less variable to factors like age or acute kidney injury, rendering it potentially more reliable in the field of congenital cardiac surgery.
Eligibility
Inclusion Criteria2
- Consented for cardiopulmonary bypass surgery for cardiac reason
- Conversational skills in German (by child and/or representative) to be able to fully understand and sign a written consent in German language
Exclusion Criteria4
- Know genetic life limiting conditions
- Syndrome patients who are scheduled or highly likely to be operated on more than one organ
- Body weight at time of surgery less than 2.5 kg
- Being recruited and enrolled for an interventional study protocol
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07029230